Stockscreener 앱 받기
7.94
3.76%
-0.31
시장 영업 전:
7.90
-0.04
-0.50%
Cadrenal Therapeutics Inc 주식(CVKD)의 최신 뉴스
Cadrenal Therapeutics to conduct partnering and investor meetings - marketscreener.com
Cadrenal Therapeutics To Conduct Partnering And Investor Meetings - TradingView — Track All Markets
Cadrenal Therapeutics, Inc. Management to Hold Investor and Partner Meetings at the 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
Biotech developing new blood thinners meets partners at major health event - Stock Titan
Cadrenal Therapeutics announces new securities purchase agreement - MSN
Cadrenal Therapeutics Announces New Securities Purchase Agreement - TipRanks
Understanding the Setup: (CVKD) and Scalable Risk - news.stocktradersdaily.com
Cadrenal Therapeutics acquires VLX-1005 from Veralox - MSN
CVKDCadrenal Therape Latest Stock News & Market Updates - Stock Titan
Cadrenal's Quiet Expansion Play Is Starting to Get Loud - Voice of Alexandria
Cadrenal Therapeutics (NASDAQ: CVKD) adds HIT, Factor XIa drugs in quiet expansion - Stock Titan
Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market - guardonline.com
Cadrenal Therapeutics (NASDAQ: CVKD) builds multi-asset anticoagulation platform in $40B market - Stock Titan
Cadrenal Therapeutics acquires late-stage drug assets from Maryland biotech - The Business Journals
Cadrenal Therapeutics acquires VLX-1005 for heparin-induced thrombocytopenia - TipRanks
Cadrenal Therapeutics acquires first-in-class HIT treatment from Veralox - Investing.com
Cadrenal Therapeutics Acquires VLX-1005 from Veralox - TipRanks
Cadrenal Therapeutics acquires first-in-class HIT treatment from Veralox By Investing.com - Investing.com Canada
Cadrenal Therapeutics acquires VLX-1005, a first-in-class Phase 2 12-LOX inhibitor for patients with heparin-induced thrombocytopenia - marketscreener.com
Cadrenal Therapeutics (Nasdaq: CVKD) adds Phase 2 12-LOX HIT therapy with FDA Fast Track - Stock Titan
Cadrenal Therapeutics (CVKD) Stock Analysis Report | Financials & Insights - Benzinga
Aug Gainers: Can Cadrenal Therapeutics Inc stock deliver strong Q4 earnings2025 Sector Review & Daily Momentum Trading Reports - moha.gov.vn
Is Cadrenal Therapeutics Inc. stock safe for conservative investorsGap Up & Weekly Market Pulse Updates - Newser
Why Cadrenal Therapeutics Inc. stock attracts global investorsGap Up & Fast Entry Momentum Trade Alerts - Newser
The Technical Signals Behind (CVKD) That Institutions Follow - news.stocktradersdaily.com
Can Cadrenal Therapeutics Inc. stock deliver strong Q4 earningsQuarterly Portfolio Summary & Daily Stock Trend Watchlist - Newser
Cadrenal Therapeutics, Inc. (CVKD) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Cadrenal Therapeutics appoints PTC Therapeutics CMO to board By Investing.com - Investing.com Australia
Cadrenal Therapeutics appoints Dr. Lee Golden to board of directors - marketscreener.com
Cadrenal Therapeutics Appoints Dr. Golden to Board - TipRanks
Cadrenal Therapeutics Appoints New Director - TradingView
Cadrenal Therapeutics, Inc. Appoints Dr. Lee Scott Golden to Board of Directors - Quiver Quantitative
Cadrenal Therapeutics appoints PTC Therapeutics CMO to board - Investing.com
Cadrenal Therapeutics, Inc. Appoints Lee Scott Golden, M.D. as Independent Director and Member of Science and Technology Committee - marketscreener.com
Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors - Sahm
Is Cadrenal Therapeutics Inc. stock affected by interest rate hikes2025 Risk Factors & Real-Time Volume Spike Alerts - BỘ NỘI VỤ
Cadrenal Therapeutics (CVKD) Stock Price, News & Analysis - MarketBeat
Will Cadrenal Therapeutics Inc. stock sustain high P E ratiosWeekly Investment Summary & Smart Allocation Stock Tips - BỘ NỘI VỤ
Precision Trading with Cadrenal Therapeutics Inc. (CVKD) Risk Zones - news.stocktradersdaily.com
Why Cadrenal Therapeutics Inc. stock could see breakout soonJuly 2025 Spike Watch & Growth Focused Stock Reports - newser.com
Institutional scanner results for Cadrenal Therapeutics Inc.2025 Earnings Impact & Step-by-Step Trade Execution Guides - newser.com
Is Cadrenal Therapeutics Inc. stock a good choice for value investors2025 Sector Review & Safe Entry Zone Tips - newser.com
Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida’s Executive of the Year Award - The Manila Times
Agilent Technologies (NYSE: A) Debuts Altura Ultra Inert HPLC With 2x Sensitivity - Stock Titan
Detecting price anomalies in Cadrenal Therapeutics Inc. with AITreasury Yields & Fast Gaining Stock Reports - newser.com
What the charts say about Cadrenal Therapeutics Inc. todayWatch List & Daily Stock Trend Watchlist - newser.com
Is Cadrenal Therapeutics Inc. stock attractive for retirement portfolios2025 Breakouts & Breakdowns & Risk Managed Investment Entry Signals - newser.com
Cadrenal Therapeutics Receives Legal Opinion From Blank Rome LLP On ?Validity Of Share Offering - MarketScreener
Cadrenal Therapeutics Announces New Stock Offering Program - TipRanks
Cadrenal Therapeutics IncBlank Rome LLP issued legal opinion on $3,438,062 sharesSEC filing - MarketScreener
[8-K] Cadrenal Therapeutics, Inc. Reports Material Event | CVKD SEC FilingForm 8-K - Stock Titan
0.18%
0.62%
자본화:
|
볼륨(24시간):